# Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

> **NCT06719973** · PHASE1 · WITHDRAWN · sponsor: **EMD Serono Research & Development Institute, Inc.**

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** M9466
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Atezolizumab
- **DRUG:** M9446
- **DRUG:** M9446
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06719973
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05-14
- **Primary completion:** 2025-05-14
- **Final completion:** 2025-05-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons.
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719973, "Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT06719973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*